Shots:

• The company has initiated a P-III ESLIM-01 trial to evaluate the efficacy and safety of HMPL-523 in 180 adult patients with ITP. The study is based on the results of the P-Ib study in patients with the same indication
• The 1EPs of the study is the DRR. The 2EPs and exploratory EPs include ORR, the incidence of treatment-emergent AEs, and patient QoL improvement
• Additionally, the company currently obtains all rights to HMPL-523 globally & the therapy is being evaluated in indolent NHL and multiple subtypes of B-cell malignancies in the US, China, US & EU. The company also plans to assess the therapy for patients with the wAIHA & other autoimmune disorder

 ­ | Ref: Hutchmed | Image: Globe Newswire